Accelerator Program Relaunches Oct. 15 with Expanded Focus on AI and Healthcare

Translate to Spanish or other 102 languages!

AltaCair Foundation, in partnership with Genentech as the 2026 co-host, will host its fourth annual Accelerator summit on Thursday, October 15, 2026, from 8:00 a.m. to 12:00 p.m. at the Harlingen Convention Center. Image for illustration purposes
AltaCair Foundation, in partnership with Genentech as the 2026 co-host, will host its fourth annual Accelerator summit on Thursday, October 15, 2026, from 8:00 a.m. to 12:00 p.m. at the Harlingen Convention Center. Image for illustration purposes
- Advertisement -

EDINBURG, Texas — AltaCair Foundation, in partnership with Genentech as the 2026 co-host, will host its fourth annual Accelerator summit on Thursday, October 15, 2026, from 8:00 a.m. to 12:00 p.m. at the Harlingen Convention Center.

Accelerator 2026: Bridging Al & Health Outcomes will bring together healthcare, policy, nonprofit, technology and community leaders to explore how artificial intelligence can be used responsibly and practically to improve healthcare access, communication, and community health outcomes.

The half-day summit will feature keynote speakers and panel discussions focused on whole-person care, social determinants of health, social impact and stronger community collaboration.

- Advertisement -

“Artificial intelligence is rapidly changing healthcare, but the conversation must remain centered on people,” said Dr. Rashmi Chandran, CEO of AltaCair Foundation. “Accelerator 2026 will create space for leaders across sectors to explore how innovation can help remove barriers, strengthen access and improve health outcomes for communities throughout the Rio Grande Valley.”

Accelerator was created to bring regional leaders together around the issues shaping health and well-being in the Rio Grande Valley. Now entering its fourth year, the summit continues to turn conversation into collaboration and community-centered action.

About AltaCair Foundation

AltaCair Foundation is a Rio Grande Valley nonprofit organization working to create a healthier region by fostering collaborative partnerships that address the basic healthcare needs of underserved communities. Through community resource fairs, educational initiatives, regional convenings and access-focused programs, AltaCair connects organizations, resources and residents to create meaningful community impact.

- Advertisement -

Additional information regarding registration, speakers and sponsorship opportunities found at https://altacairaccelerator.com

Courtesy image
- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Robotic Surgery Program Expanded at STHS McAllen

From smaller incisions and less pain to shorter hospital stays and faster recovery times, robotic-assisted surgery is changing the way patients experience surgical care.

Texas Oncology to Host Breast Cancer Awareness Symposium in McAllen. FULL TO CAPACITY. NO MORE ROOM.

The Breast Cancer Awareness Symposium 2026 is an educational and networking event hosted by Texas Oncology and sponsored by Caris Life Sciences, bringing together oncology specialists, surgeons, advanced practice providers, and community healthcare professionals to discuss the latest advances in breast cancer prevention, diagnosis, treatment, survivorship, and reconstruction. The symposium's theme, "Breast Cancer 2026: Early Detection, Modern Care, and Survivorship Through Community Partnership," highlights the importance of multidisciplinary collaboration and patient-centered care

Highway Crash Leads to Unexpected STC Connection

What began as a flat tire on the side of a highway turned into a frightening collision and an unexpected encounter for South Texas College faculty member Jesus Amaya, when the paramedic who responded to the scene turned out to be one of STC’s graduates.

FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.
- Advertisement -